[HTML][HTML] LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE* 3Leiden mice: time course and mechanismss⃞
L Verschuren, J de Vries-van der Weij, S Zadelaar… - Journal of lipid …, 2009 - ASBMB
The aim of this study was to define the anti-atherosclerotic role of liver-X-receptors (LXRs)
under lesion progressive and lesion regressive conditions, to establish a temporal line of
events, and to gain insights into the mechanisms underlying the anti-atherogenic potency of
LXRs. We used apoE* 3Leiden (E3L) mice to comprehensively and time-dependently
dissect how T0901317, an LXR-agonist, inhibits initiation and progression of atherosclerotic
lesions and regresses existing lipid-and macrophage-rich lesions. T0901317 suppresses …
under lesion progressive and lesion regressive conditions, to establish a temporal line of
events, and to gain insights into the mechanisms underlying the anti-atherogenic potency of
LXRs. We used apoE* 3Leiden (E3L) mice to comprehensively and time-dependently
dissect how T0901317, an LXR-agonist, inhibits initiation and progression of atherosclerotic
lesions and regresses existing lipid-and macrophage-rich lesions. T0901317 suppresses …